# A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer

Source: https://onco.cc/trials/nct07766018/  
OnCo record `nct07766018` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Elacestrant in advanced solid tumours, run by Stemline Therapeutics, Inc., now recruiting.

## Summary

A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer is a phase 2 interventional study registered as NCT07766018 by Stemline Therapeutics, Inc., with 70 participants planned, started 2026-08-18 and due to reach its primary completion in 2028-10. Interventions recorded: Elacestrant.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07766018
- Phase: 2
- Setting: A Phase 2 Open-Label, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of Elacestrant Monotherapy for the Treatment of Japanese Participants With ER+/HER2- Advanced or Metastatic Breast Cancer With ESR1-mutation Following CDK4/6 Inhibitor Therapy
- Sponsor: Stemline Therapeutics, Inc.
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT07766018: https://clinicaltrials.gov/study/NCT07766018

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Elacestrant](https://onco.cc/drugs/elacestrant/)
- companies: [Menarini / Stemline](https://onco.cc/companies/menarini/)

---
JSON: https://onco.cc/api/v1/entities/nct07766018.json